聚乙二醇化干扰素α-2a对HCV基因Ⅰ型和非基因Ⅰ型感染的慢性丙肝患者的疗效比较  

Comparative effectiveness research of pegylated interferon alpha-2a in chronic hepatitis C patients with HCV genotype Ⅰ and non-genotype Ⅰ infection

作　　者：彭芳[1] 柴晓东[1] 王小红[1] PENG Fang;CHAI Xiaodong;WANG Xiaohong(Department of Infectious Diseases,The First Hospital of Shizuishan,Shizuishan 753200,China)

机构地区：[1]宁夏回族自治区石嘴山市第一人民医院感染性疾病科,宁夏石嘴山753200

出　　处：《宁夏医学杂志》2020年第4期344-346,共3页Ningxia Medical Journal

摘　　要：目的聚乙二醇化干扰素α-2a对丙型肝炎病毒(HCV)基因Ⅰ型和非HCVⅠ型感染的慢性丙型肝炎(CHC)的临床疗效。方法将128例分为CHC患者分为HCV基因Ⅰ型组与非基因Ⅰ型组,每组64例。2组均采用标准化治疗方案聚乙二醇化干扰素α-2a联合利巴韦林治疗,比较2组的治疗效果。结果非基因Ⅰ型组RVR、EVR、ETVR及SVR均明显高于HCV基因Ⅰ型组;低病毒载量患者中,HCV基因Ⅰ型组与非基因Ⅰ型组RVR、EVR、ETVR和SVR之间差异无统计学意义(P>0.05);高病毒载量患者中,非基因Ⅰ型组RVR、EVR、ETVR和SVR均明显高于HCV基因Ⅰ型组;治疗后2组ALT、AST指标均较治疗前明显改善,但非基因Ⅰ型组各项指标均优于HCV基因Ⅰ型组。2组患者治疗中均出现发热、失眠等不良反应,均耐受治疗,2组间比较差异无统计学意义(P>0.05);停药随访期间,2组患者不良反应均逐渐消失。结论聚乙二醇化干扰素α-2a联合利巴韦林治疗方案对HCV非基因Ⅰ型的抗病毒效果较好,而对于基因Ⅰ型未取得较好抗病毒效果则要及时选择其他治疗方案。Objective To evaluate the clinical efficacy of pegylated interferon α-2a in thetreatment of chronic hepatitis C with hepatitis C virus(HCV)genotype I and non-HCV type I(CHC)infection.Methods 128 cases of patients with CHC were treated in our hospital,64 cases in HCV genotype I group and 64 cases in non genotype I group.The two groups were treated with the standardized regimen of pegylated interferonα-2a combined with ribavirin,and the therapeutic effects of the two groups were compared.Results RVR,EVR,ETVR and SVR in non genotype I group were significantly higher than the HCV genotype Ⅰ group(P<0.05).In patients with low viral load,there was no significant different in RVR,EVR,ETVR and SVR between the HCV genotype type Ⅰ and non genotype Ⅰ groupG(P>0.05).In patients with high viral load,RVR,EVR,ETVR and SVR in non-genotype Ⅰ group were significantly higher than those in HCV genotype Ⅰ group(P<0.05).ALT,AST were significantly improved than before treatment(P<0.05),but the indicators in non genotype Ⅰ groups were better than these in the HCV genotype I group(P<0.05).In both groups,there were some adverse reactions,such as fever,insomnia,which were tolerated treatment,and there was no statistical significant between the two groups(P>0.05),During the follow-up period of withdrawal,patients with adverse reactions gradually disappeared.Conclusion The antiviral effect of pegylated interferon alpha-2a combined with ribavirin in non-genotype HCV is better,and other antiviral effects of genotype Ⅰ should be selected in time.

关 键 词：聚乙二醇化干扰素Α-2A HCV基因 慢性丙型肝炎 

分 类 号：R512.63[医药卫生—内科学]